Skip to content
HowShorted

PTC Therapeutics, Inc. short interest in 2024

In 2024, PTC Therapeutics, Inc.'s disclosed short interest ran from 13.22% of shares outstanding on 12 Jan 2024 to 5.45% on 31 Dec 2024, a change of -7.77 percentage points. The year's high was 15.11% on 29 Feb 2024 and its low 5.45% on 31 Dec 2024, averaging 9.50% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 16.27 days on 15 Apr 2024. Full history: PTC Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for PTC Therapeutics, Inc. in 2024

2024 in figures

Start of year
13.22% (12 Jan 2024)
End of year
5.45% (31 Dec 2024)
Change
-7.77 pp
High
15.11% (29 Feb 2024)
Low
5.45% (31 Dec 2024)
Average
9.50%
Highest days to cover
16.27 (15 Apr 2024)
SEC filings marked
9

Every report in 2024

PTC Therapeutics, Inc. short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 202413.22%9.47results (8-K)
31 Jan 202414.63%8.25
15 Feb 202413.76%11.98
29 Feb 202415.11%13.3010-K filed, results (8-K)
15 Mar 202414.43%10.39
28 Mar 202413.60%15.83
15 Apr 202413.52%16.27
30 Apr 202412.94%7.8510-Q filed, results (8-K)
15 May 202411.63%12.40
31 May 20249.76%7.51
14 Jun 20249.59%9.43
28 Jun 20247.30%3.66
15 Jul 20247.77%10.19
31 Jul 20247.48%9.22
15 Aug 20247.73%10.7510-Q filed, results (8-K)
30 Aug 20247.31%13.22
13 Sep 20246.79%9.61
30 Sep 20245.55%5.69
15 Oct 20246.06%5.27
31 Oct 20246.35%6.47
15 Nov 20246.06%6.1710-Q filed, results (8-K)
29 Nov 20245.96%6.32
13 Dec 20245.95%4.39
31 Dec 20245.45%7.92

See also: PTC Therapeutics, Inc.'s full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.